FY2030 Earnings Forecast for AURA Issued By HC Wainwright

Aura Biosciences, Inc. (NASDAQ:AURA) – HC Wainwright issued their FY2030 earnings estimates for shares of Aura Biosciences in a report issued on Monday, March 30th. HC Wainwright analyst A. Maldonado forecasts that the company will earn ($0.35) per share for the year. HC Wainwright currently has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aura Biosciences in a report on Friday, March 27th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $20.50.

Aura Biosciences Price Performance

NASDAQ:AURA opened at $6.70 on Thursday. Aura Biosciences has a 12 month low of $4.34 and a 12 month high of $7.48. The firm has a market capitalization of $429.81 million, a PE ratio of -3.74 and a beta of 0.35. The business’s fifty day moving average price is $5.90 and its 200 day moving average price is $5.87.

Institutional Investors Weigh In On Aura Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd acquired a new position in Aura Biosciences in the first quarter valued at $137,000. Invesco Ltd. purchased a new stake in shares of Aura Biosciences in the 2nd quarter valued at about $76,000. Resolute Capital Asset Partners LLC purchased a new stake in shares of Aura Biosciences in the 2nd quarter valued at about $570,000. B Group Inc. boosted its position in shares of Aura Biosciences by 21.2% in the 2nd quarter. B Group Inc. now owns 572,576 shares of the company’s stock valued at $3,584,000 after purchasing an additional 100,000 shares during the period. Finally, Nantahala Capital Management LLC boosted its position in shares of Aura Biosciences by 67.1% in the 2nd quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company’s stock valued at $13,257,000 after purchasing an additional 850,000 shares during the period. 96.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 47,648 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total value of $241,098.88. Following the completion of the transaction, the insider owned 409,815 shares in the company, valued at approximately $2,073,663.90. This represents a 10.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Amy Elazzouzi sold 8,549 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total transaction of $43,257.94. Following the completion of the transaction, the senior vice president directly owned 75,532 shares in the company, valued at $382,191.92. This trade represents a 10.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 123,076 shares of company stock valued at $618,783 in the last quarter. Company insiders own 6.30% of the company’s stock.

About Aura Biosciences

Aura Biosciences is a clinical?stage biopharmaceutical company focused on the development of novel virus?like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non?ophthalmic settings, leveraging precision activation via near?infrared light to induce localized tumor cell apoptosis and stimulate anti?tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.